Drug Development Questions And The FDA - The End Of The Black Hole

March 31, 2015

Commonly during drug development, significant issues arise for which FDA input is desired but that do not merit a full face-to-face multidisciplinary milestone meeting. In many cases, sponsors are reluctant to reach out to the FDA because of a concern that their questions will disappear into a black hole while the FDA focuses on PDUFA time-line mandated activities. The new FDA guidance, Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products, appears to provide some degree of certainty around the process for requesting this type of input and time frames for responses from the FDA. As described in the section of the guidance on Type C meetings, sponsors may request a written response to these types of questions and if the FDA agrees to answer the questions, the meeting granted letter will specify the date that the written responses are to be transmitted to the sponsor (provided that adequate briefing information is sent to the FDA in a timely manner). While the 75-day time frame for a response is probably not as quick as most sponsors would like, it does provide definition to a process that a company can plan around. As with all FDA interactions, we recommend taking the time to formulate the strategy which best aids in successful drug development, incorporating questions such as:

  • Whether requesting a written response or a full meeting with the FDA provides the best strategic option for the sponsor; and
  • How best to position questions and background materials so that written responses and/or meeting minutes from the Agency fully address and answer the sponsor’s questions.

Learn more about ProPharma Group's regulatory strategy and submission services. If you have any questions or thoughts on this blog post or others, please contact us




Medical Device Agency Alerts

March 31, 2015

Draft Guidance: Requesting Nonbinding Feedback After an FDA Inspection of Your Medical Device Establishment

On Tuesday, February 19th, FDA published a draft guidance for medical device makers which identifies a process for companies to request nonbinding feedback on certain FDA Form 483 deficiencies noted...

Read More
Agency Alerts General Regulatory

March 31, 2015

Will FDA Change the Definition of “Intended Use”?

FDA released proposed regulation that would allow sponsors to determine if their product is a drug/device, or if it is not a drug/device. Last week, the Agency announced a proposed rule “to provide...

Read More
Agency Alerts General Regulatory

March 31, 2015

Compassionate Use for Investigational Drugs: FDA to Improve Awareness & Transparency of Expanded Access Programs

The Reagan-Udall Foundation for the FDA (RUF), a non-profit organization created to help the FDA accomplish its mission, is in the process of developing an online Navigator to help patients and...

Read More